Newmarket Scientific has introduced Bioo Scientific's T3 Conjugation Kit for targeted in vivo delivery of siRNA or any other RNAi agent.
The T3 Conjugation Kit can also be used for targeted in vitro delivery of siRNA in primary cells or cell lines that have mixed cell populations.
RNAi allows researchers to directly observe the effects of the loss of function of specific genes in mammalian systems.
However, achieving efficient in vivo delivery of siRNA to the appropriate target cell has been a major hurdle in the advancement of using RNAi in gene-function studies and as a therapeutic agent.
This hurdle can now be easily overcome using the T3 Conjugation Kit.
The T3 technology functions by conjugating a T3 carrier to an antibody that is specific to a receptor or other extracellular domain specific to the targeted cell or tissue type.
The T3 carrier-antibody conjugate can then be loaded with an RNAi agent such as siRNA or miRNA.
The RNAi agent-loaded T3 conjugate may then be administered systemically or locally to an animal (or cultured cells), where it binds to and is internalised by cells recognised by the antibody.
Once inside the cell, the RNAi agent is designed for release from T3, allowing silencing of its intended target.
The T3 Conjugation Kit technology will propel the validation of in vivo work, leading to a better understanding of cellular pathways, the identification of novel drug targets and the ability to more efficiently deliver RNAi agents as drugs.
